

HEALTH AND DRUG ALERTS

Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose

Reason for posting: A change in the prescribing information for venlafaxine has been issued by the US manufacturer, based on concerns that the antidepressant drug has been associated, in cases of overdose, with an increased risk of death compared with selective serotonin reuptake inhibitors (SSRIs).

The drug: Venlafaxine, a serotonin and noradrenalin reuptake inhibitor, is widely used in Canada for the treatment of DSM-IV-defined major depressive, generalized anxiety and social anxiety disorders in adults. It is generally well tolerated but shares several of the adverse effects of SSRIs, including gastrointestinal upset, sweating, dry mouth, sedation and sexual dysfunction. Additionally, venlafaxine has a known association with blood pressure elevation in some 3%–4% of patients who use the sustained release format and 2%–13% of those who take the immediate-release preparation. Concerns about a higher fatality rate in overdose has emerged over the past 4 years from information provided by administrative database studies.^{1–4}

Relative risk estimates for fatal overdose vary within and between classes of

antidepressants. Tricyclic antidepressants (TCAs) have consistently been associated with the highest toxicity in overdose. SSRIs, on the other hand, are the least toxic in overdose, with approximately one-tenth the death rates associated with TCAs.¹ Venlafaxine appears to fall somewhere in between (Table 1). Putting the numbers into perspective, the annual suicide rate in Canada is about 13.5 per 100 000 in the general population; higher, among patients receiving psychiatric treatment. Deliberate antidepressant overdoses account for 4%–7% of all suicides;¹ one-third of fatal antidepressant overdoses also include alcohol or other drugs.²

The reasons for the increased overdose fatalities associated with venlafaxine are not entirely clear. Competing explanations include a true toxicity effect versus a “spurious” effect related to its use in higher-risk groups than those prescribed SSRIs. Some combination of these is also possible. The former explanation is supported by case reports linking cardiac illness and venlafaxine overdose.³ The latter is supported by a study of data from the United Kingdom’s General Practice Research Database, in which patients prescribed ven-

lafaxine were more likely than patients prescribed SSRIs to have been admitted to hospital for depression, to have displayed suicidal behaviour and to have received co-prescriptions of antipsychotic medications.⁵ Unfortunately, the data did not include specifics on the doses consumed, duration of drug use or comorbid illnesses.

What to do: The US manufacturer has issued a warning stating that “prescriptions for Effexor should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.” This is difficult to apply across a wide spectrum of prescribing patterns. If venlafaxine is used as a second- or third-line drug for the treatment of depression, its use may signal the need for a more in-depth assessment of suicide risk and perhaps more intensive treatment.

Regardless of the role of patient risk factors, it is important to be aware of plausible arguments that venlafaxine is more toxic in overdose than SSRIs but less so than TCAs. A definitive explanation of the observed effect will have to wait upon more specific information.

Dorian Deshauer
CMAJ

REFERENCES

1. Buckley NA, McManus PR. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of

Table 1: Database studies of antidepressant-related deaths in relation to antidepressant prescriptions

Study	Administrative database	Risk measure	Type of antidepressant (95% CI)		
			Tricyclics	Venlafaxine	SSRIs
Buckley and McManus 2002	General Register Office for Scotland; Office for National Statistics (England and Wales) 1993-1999	Deaths per million prescriptions	34.8 (33.5-36.2)	13.2 (9.2-18.5)	1.6 (1.3-2.0)
Morgan et al 2004	Office for National Statistics (England and Wales) 1993-2002	Deaths per million prescriptions	30.1 (29.0-31.3)	8.5 (6.6-11.0)	1 (0.7-1.2)
Cheeta et al 2004	National Programme of Substance Abuse Deaths (England and Wales, coroner's data) 1998-2000	Mentions in death reports per million prescriptions	12*	13*	2*
Koski et al 2005	Finnish National Agency of Medicine: autopsy lab results, national prescription data 1995-2002	Fatal toxicity index (deaths/1000 people per defined daily dose per year)	Doxepin† 22 (19-25) Amitriptyline 12 (10-13)	4.4 (3.0-6.3)	Citalopram† 1.2 (1.0-1.5) Fluoxetine 0.33 (0.19-0.53)

Note: CI = confidence interval, SSRIs = selective serotonin reuptake inhibitors.

*Raw datum; no confidence interval given.

†Summary data unavailable for antidepressant category.

- UK mortality data. *BMJ* 2002;325:1332-3.
2. Morgan O, Griffiths C, Baker A, et al. Fatal toxicity of antidepressants in England and Wales, 1993-2002. *Health Stat Q* 2004;(23):18-24.
 3. Cheeta S, Schifano F, Oyefeso A, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. *Br J Psychiatry* 2004;184:41-7.
 4. Koski A, Vuori E, Ojanpera I. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. *Int J Legal Med* 2005;119:344-8.
 5. Mines D, Hill D, Yu H, et al. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. *Pharmacoepidemiol Drug Saf* 2005;14:367-72.

All Health and Drug Alerts are posted online ahead of print and are available at www.cmaj.ca. This article was posted on Dec. 13, 2006.

Canadian Adverse Reaction Newsletter Bulletin canadien des effets indésirables

To receive the Newsletter and health product Advisories free by email, join Health Canada's **MedEffect** mailing list. Go to www.hc-sc.gc.ca/dhp-mps/medeff/subscribe-abonnement/index_e.html.

Inscrivez-vous à la liste **MedEffet** de Santé Canada pour recevoir gratuitement par courriel le Bulletin et les Avis au sujet des produits de santé.

Rendez-vous à l'adresse
www.hc-sc.gc.ca/dhp-mps/medeff/subscribe-abonnement/index_f.html.

**Report adverse reactions toll free to
Health Canada • Signaler sans frais des
effets indésirables à Santé Canada**

Tel./Tél. : 866 234-2345
Fax/Téléc. : 866 678-6789



Health
Canada

Santé
Canada

Canada